Caribou Biosciences, Inc. (CRBU) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $11.00K; Additional Paid in CapitalUSD $744.04M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-71.00K; Retained Earnings (Accumulated Deficit)USD $-645.88M.
- 2026-03-31: Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $723.63M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-23.00K; Retained Earnings (Accumulated Deficit)USD $-621.60M.
- 2025-12-31: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in CapitalUSD $718.58M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $103.00K; Retained Earnings (Accumulated Deficit)USD $-596.51M.
- 2025-09-30: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in CapitalUSD $711.77M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $93.00K; Retained Earnings (Accumulated Deficit)USD $-570.03M.
Caribou Biosciences, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.00K | $744.04M | $-71.00K | $-645.88M | $98.10M | 3 month · $2.48M | (m) | (m) |
| 2026-03-31 | $10.00K | $723.63M | $-23.00K | $-621.60M | $102.02M | 3 month · $2.36M | (m) | (m) |
| 2025-12-31 | $9.00K | $718.58M | $103.00K | $-596.51M | $122.17M | (m) | (m) | (m) |
| 2025-09-30 | $9.00K | $711.77M | $93.00K | $-570.03M | $141.84M | 3 month · $2.93M | (m) | (m) |
| 2025-06-30 | $9.00K | $708.56M | $40.00K | $-542.48M | $166.13M | 3 month · $3.13M | (m) | (m) |
| 2025-03-31 | $9.00K | $705.43M | $167.00K | $-488.38M | $217.22M | 3 month · $3.88M | (m) | (m) |
| 2024-12-31 | $9.00K | $701.08M | $255.00K | $-448.39M | $252.95M | 12 month · $16.71M | (m) | (m) |
| 2024-09-30 | $9.00K | $693.30M | $789.00K | $-412.90M | $281.20M | 3 month · $4.07M | (m) | (m) |
| 2024-06-30 | $9.00K | $688.99M | $-319.00K | $-378.22M | $310.46M | 3 month · $4.74M | (m) | (m) |
| 2024-03-31 | $9.00K | $684.12M | $-322.00K | $-340.52M | $343.29M | 3 month · $3.99M | (m) | (m) |
| 2023-12-31 | $8.00K | $667.65M | $30.00K | $-299.29M | $368.40M | 12 month · $13.75M | (m) | (m) |
| 2023-09-30 | $8.00K | $664.02M | $-981.00K | $-264.78M | $398.27M | 3 month · $3.48M | $0.00 | (m) |
| 2023-06-30 | $6.00K | $525.37M | $-1.14M | $-254.78M | $269.46M | 3 month · $3.58M | $0.00 | (m) |
| 2023-03-31 | $6.00K | $504.25M | $-730.00K | $-225.26M | $278.27M | 3 month · $3.13M | $0.00 | (m) |
| 2022-12-31 | $6.00K | $499.60M | $-1.52M | $-197.22M | $300.87M | 12 month · $11.71M | $0.00 | (m) |
| 2022-09-30 | $6.00K | $496.37M | $-2.04M | $-170.23M | $324.11M | 3 month · $2.67M | $0.00 | (m) |
| 2022-06-30 | $6.00K | $493.04M | $-1.58M | $-143.58M | $347.89M | 3 month · $2.92M | $0.00 | 6 month · $1.20M |
| 2022-03-31 | $6.00K | $489.76M | $-1.09M | $-116.88M | $371.80M | 3 month · $3.02M | $0.00 | 3 month · $1.20M |
| 2021-12-31 | $6.00K | $485.75M | $-135.00K | $-97.79M | $387.82M | 12 month · $3.45M | $0.00 | (m) |
| 2021-09-30 | $6.00K | $483.71M | (m) | $-79.31M | $404.40M | 3 month · $935.00K | (m) | (m) |
| 2021-06-30 | $1.00K | $10.65M | (m) | $-58.34M | $-47.69M | 3 month · $593.00K | (m) | 1 month · $1.20M 6 month · $1.20M |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-35.69M | 3 month · $343.00K | (m) | (m) |
| 2020-12-31 | $1.00K | $7.43M | $0.00 | $-30.87M | $-23.44M | 12 month · $1.00M | $0.00 | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-11.21M | 3 month · $248.00K | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-3.67M | 3 month · $286.00K | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-2.10M | 3 month · $237.00K | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $7.46M | 12 month · $1.23M | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $29.95M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |